Log In
BCIQ
Print this Print this
 

Chimeric anti-CD20 mAb (SCT400)

  Manage Alerts
Collapse Summary General Information
Company Sinocelltech Ltd.
DescriptionChimeric anti-CD20 mAb
Molecular Target CD20
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationNon-Hodgkin's lymphoma (NHL)
Indication DetailsTreat non-Hodgkin's lymphoma (NHL)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today